New hope for myelofibrosis patients who fail current therapies
Disease control
Recruiting now
This early-stage study tests an experimental pill, AJ1-11095, in people with a bone marrow cancer called myelofibrosis. Participants must have already tried a standard JAK2 inhibitor without success. The main goals are to check the drug's safety and find the best dose for future …
Phase: PHASE1 • Sponsor: Ajax Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC